Skip to main content
Xinjian Chen

Xinjian Chen, MD, PhD

Academic Office Information

xinjian.chen@path.utah.edu

About Me

We study targeted therapy in combination with immunotherapy for cancer treatment, using graphene oxide-formulated anticancer antibodies along with tumor-targeted delivery of immune cytokines. Our goal is to convert tumor necroptosis into tumor vaccine in situ to overcome intratumor tolerogenic microenvironment. We also investigate mechanisms of cancer cell necroptosis brought about by graphene oxide-formulation anticancer antibodies.

3i Bridge/Pillar: Cancer

Keywords: anticancer antibodies, graphene oxide, necroptosis